The Deubiquitinase USP22‐Stabilized COL17A1 Promotes Lung Adenocarcinoma Progression
The Clinical Respiratory Journal · 2024
DOI: 10.1111/crj.13824 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Clinical Respiratory Journal, 2024. Verfasst von Guangxi Chen und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Medicine, Jiujiang City Key Laboratory of Cell Therapy, Jiujiang NO.1 People's Hospital, Jiujiang, China. Hauptthemen laut MEDLINE: Ubiquitin Thiolesterase, Lung Neoplasms, Disease Progression, Cell Proliferation. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Lung adenocarcinoma (LUAD) is a highly aggressive and rapidly fatal malignancy worldwide. Collagen XVII (COL17A1) has been implicated in various protumorigenic processes. However, the functions and mechanisms of COL17A1 in LUAD progression still remain elusive.
Methods
COL17A1 and ubiquitin‐specific protease 22 (USP22) mRNA analysis was performed by quantitative PCR, and their protein levels were detected by immunoblotting and immunohistochemistry. The functional influence was evaluated by determining cell viability, proliferation, apoptosis, invasion, migration, and ferroptosis in vitro, as well as xenograft growth in vivo. Co‐immunoprecipitation (Co‐IP) and IP experiments were used to examine the USP22/COL17A1 interaction and COL17A1 deubiquitination. Cycloheximide treatment was used to analyze COL17A1 protein stability.
Results
COL17A1 and USP22 were upregulated in human LUAD tissues and cell lines. Functionally, COL17A1 knockdown acted for the suppression of LUAD cell growth, invasion, and migration as well as promotion of cell apoptosis and ferroptosis in vitro. COL17A1 knockdown could diminish the tumorigenicity of LUAD cells in vivo. Mechanistically, USP22 stabilized and upregulated COL17A1 by enhancing the deubiquitination of COL17A1. Additionally, reexpression of COL17A1 could reverse USP22 silencing‐induced phenotype changes of LUAD cells in vitro.
Conclusion
Our findings demonstrate that USP22‐stabilized COL17A1 possesses oncogenic activity in LUAD. We propose that USP22 and COL17A1 would be potential targets for the establishment of therapeutic approaches against LUAD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of General Medicine, Jiujiang City Key Laboratory of Cell Therapy, Jiujiang NO.1 People's Hospital, Jiujiang, China.
- Department of Jiulong Community Health Service Centre, Jiujiang City Key Laboratory of Cell Therapy, Jiujiang NO.1 People's Hospital, Jiujiang, China.
- Department of Chronic Hepatology, Jiujiang Third People's Hospital, Jiujiang, China.
- Department of Respiratory and Critical Care Medicine, Jiujiang Third People's Hospital, Jiujiang, China.
ORCID-Profile: Huifeng Li
Zitieren
APA
Chen, G., Du, D., Wang, H., & Li, H. (2024). The Deubiquitinase USP22‐Stabilized COL17A1 Promotes Lung Adenocarcinoma Progression. The Clinical Respiratory Journal. https://doi.org/10.1111/crj.13824
Vancouver
Chen G, Du D, Wang H, Li H. The Deubiquitinase USP22‐Stabilized COL17A1 Promotes Lung Adenocarcinoma Progression. The Clinical Respiratory Journal. 2024. doi:10.1111/crj.13824
BibTeX
@article{Chen2024,
author = {Chen, Guangxi and Du, Dandan and Wang, Haihua and Li, Huifeng},
title = {The Deubiquitinase USP22‐Stabilized COL17A1 Promotes Lung Adenocarcinoma Progression},
journal = {The Clinical Respiratory Journal},
year = {2024},
doi = {10.1111/crj.13824}
}
EUVIMED